Clinical Overview
HAS-BLED is a bedside decision-support calculation used to standardize a defined part of clinical assessment. It predicts major bleeding risk and, more importantly, prompts correction of modifiable factors in anticoagulated atrial fibrillation. The result should be interpreted with the patient’s presentation, baseline function, serial observations, laboratory method, medication exposure, and the protocol used by the treating institution. It is an aid to communication and risk stratification rather than an independent diagnosis or treatment order.
Enter contemporaneous values and confirm every unit before calculating. When physiology is changing, repeat assessment and prioritize the clinical trajectory over a single number. Document the input values alongside the result so another clinician can reproduce the calculation and recognize assumptions. Thresholds describe populations and do not remove the need to investigate discordant symptoms, examination findings, imaging, or biomarkers.
When to Use
- Adults with atrial fibrillation being considered for or receiving anticoagulation
- Structured review of modifiable bleeding risk
Limitations & Safety
Definitions of renal dysfunction, liver dysfunction, bleeding predisposition, and labile INR should follow the validated score and available longitudinal data. Validation cohorts, case mix, prevalence, and treatment era affect observed event rates. Pregnancy, extremes of age or body composition, critical illness, and major comorbidity may reduce transportability unless specifically represented in the original model. Do not extrapolate beyond the stated population or substitute this estimate for a validated local pathway.
Before acting, check for missing data, measurement error, competing diagnoses, contraindications, and time-sensitive emergencies. A low-risk label never overrides clinician concern; a high-risk label does not prove the target condition. Discuss consequential decisions with the appropriate senior or specialty team and use current regional guidance.
- A high score is not by itself a reason to withhold anticoagulation
- Some definitions require clinical judgment and current laboratory history
Formula / Scoring Criteria
HAS-BLED = Hypertension + Abnormal renal/liver function (1 each) + Stroke + Bleeding + Labile INR + Elderly >65 + Drugs/alcohol (1 each); maximum 9
Interpretation
- 0–1 — Lower: Fewer recognized bleeding factors. Routine monitoring and risk-factor review.
- 2 — Moderate: Meaningful bleeding-risk burden. Correct modifiable factors and monitor more closely.
- ≥3 — High-risk flag: Higher major-bleeding risk. Frequent review and risk modification; not an automatic anticoagulation exclusion.
Evidence & References
- Pisters R, et al. A novel user-friendly score to assess 1-year risk of major bleeding in AF. Chest. 2010.
- Lip GYH, et al. Refining clinical risk stratification for predicting stroke in atrial fibrillation. Chest. 2010.
- 2024 ESC Guidelines for management of atrial fibrillation.
Clinical FAQs
Should anticoagulation be stopped at 3 points?
No. The score flags patients for closer follow-up and modification of reversible risks.
What is labile INR?
Commonly unstable or high INRs or time in therapeutic range below about 60% while using a vitamin K antagonist.
Does it apply to DOACs?
It can structure bleeding-risk review, though labile INR is specific to vitamin K antagonist control.